Di-fluoro azepane HBV capsid assembly modulators.
Journal
Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
received:
25
04
2023
revised:
22
05
2023
accepted:
22
05
2023
medline:
2
8
2023
pubmed:
30
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
The protein that forms the inner shell of the HBV virus, known as the capsid core protein, plays a crucial role in allowing chronic HBV infections to persist. Studies have shown that disrupting the assembly of the capsid can effectively combat the virus, and small molecule drugs that target the HBV capsid assembly modulator (CAM) process have been successful in clinical trials. Herein is described a distinct series of di-fluoro azepane CAMs with exceptional potency, pharmacokinetic, and solubility properties.
Identifiants
pubmed: 37247697
pii: S0960-894X(23)00228-7
doi: 10.1016/j.bmcl.2023.129350
pii:
doi:
Substances chimiques
Antiviral Agents
0
Capsid Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
129350Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.